Ingavirin - innovative antiviral drug with a unique mechanism of action and a broad spectrum of antiviral activity, including influenza A (H1N1) pdm09. Using of Ingavirin in the first 48 hours of illness results in a significant reduction of the period of fever, intoxication and catarrhal symptoms. Ingavirin reduces viral action and significantly reduces the risk of complications.
Experimental toxicological research shows low toxicity and high safety profile of Ingavirin (LD50 greater than the therapeutic dose in more than 3000 times).
Ingavirin is not mutagenic, immunotoxic, allergic and carcinogenic, has no local irritating action.
Indications: treatment of influenza A and B, and other acute respiratory viral infections (adenovirus infection, parainfluenza, respiratory syncytial infection).
Package: 10 capsules 90 mg